|
|
|
28.11.25 - 21:12
|
Cereno Scientific: Major shareholders and new investors back the Company′s long-term strategy with equity investment at a premium (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced that major long-term shareholders and new investors have confirmed their strong support by participating in the recently communicated financing arrangement, amounting to a total of up to SEK 650 million with SEK 100 million raised in a directed share issue (the “Directed Issue”), warrants with premium strike prices that may add further equity capital of up to 200 million, and up to SEK 350...
|
|
|
28.11.25 - 21:12
|
Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 (Cision)
|
|
|
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.
Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), an innovative biotech pioneering treatments to enhance and extend...
|
|
|
28.11.25 - 18:36
|
Number of shares and votes in BioArctic AB (publ) as of November 28, 2025 (Cision)
|
|
|
Stockholm, November 28, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 4,000 Class B shares during November for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 4,000 stock options of series 2019/2028.
As of November 28, 2025, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,641,485 shares, of which 74,241,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A...
|
|
|
|
|
28.11.25 - 15:06
|
Peptonic Medical AB′s reconstruction plan approved by the Uppsala District Court (Cision)
|
|
|
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has decided to approve the Company's reconstruction plan. The court's decision will become legally binding on 19 December 2025, unless the decision is appealed to the Svea Court of Appeal before that date.
The debt settlement in the reconstruction plan is conditional upon the share issues in the plan, and vice versa. If the share issues under the reconstruction plan are not completed by the last banking day of the month that falls two months after the reconstruction plan becomes legally binding,...
|
|
|
|
|
|
|
28.11.25 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 28 November 2025 — During November 2025, 24,200 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 24,200.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,848,634 corresponding to 59,848,634 votes. As of 28 November 2025, the total number of shares in Camurus amounts to 59,872,834 corresponding to...
|
|
|
28.11.25 - 06:36
|
New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan (Cision)
|
|
|
Stockholm, Sweden, November 28, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have filed a new drug application for Leqembi (lecanemab) for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, deadly disease.
The application is based on data from multiple subcutaneous (SC)...
|
|
|
27.11.25 - 16:36
|
Publication of interim report Q1 2025/2026 (Cision)
|
|
|
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.
First quarter (2025-07-01 – 2025-09-30)
· The Group's net sales amounted to SEK 5,968,143 (143,793).
· The Group's profit after financial items amounted to SEK -37,027 (-1,468,183).
· Result per share amounted to SEK -0.00 (-0.10).*
· The solidity as of 2025-09-30 was 4% (9%).**
* The Company's result per...
|
|
|
27.11.25 - 12:48
|
Peptonic Medical AB: Plan Hearing Held at Uppsala District Court (Cision)
|
|
|
Peptonic Medical AB (publ) (“the Company”) announces that a plan hearing was held today at Uppsala District Court. During the hearing, the reconstruction plan was presented, and relevant parties had the opportunity to provide input and vote on the plan. The court's decision on whether the reconstruction plan can be adopted is expected tomorrow, Friday November 28, 2025.
At the hearing, the reconstruction administrator and the Company presented the reconstruction plan. Parts of this presentation have, as previously announced, been published on the Company's website, www.peptonicmedical.se....
|
|
|
27.11.25 - 08:30
|
Peptonic Medical AB Presents Current Sales Figures (Cision)
|
|
|
Peptonic Medical AB (publ) (“the Company”) announces current sales figures in connection with the plan hearing being held today at 10:00 AM at the Uppsala District Court. During the hearing, the reconstruction administrator and the Company will present the reconstruction plan. Parts of this presentation, including sales figures for October 2025 and accumulated for the period January through October 2025, have now been published on the Company's website.
Current sales for October 2025 amount to 2,4 MSEK and for the period January to October 2025 amount to SEK 13.6 million, compared with the...
|
|
|
27.11.25 - 07:48
|
Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 – September 30, 2025) (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q3 2025 (July 1 – September 30, 2025).
Financial overview
Cereno Scientific Group – Q3
· Net Sales were SEK 0 (0)
· Result after financial items was SEK -21 321 915 (-22 718 087)
· Earnings per share was SEK -0.07 (-0.08) before dilution and SEK -0.07 (-0.07) after...
|
|
|
|
|
27.11.25 - 07:30
|
Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 – September 30, 2025) (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q3 2025 (July 1 – September 30, 2025).
Financial overview
Cereno Scientific Group – Q3
· Net Sales were SEK 0 (0)
· Result after financial items was SEK -21 321 915 (-22 718 087)
· Earnings per share was SEK -0.07 (-0.08) before dilution and SEK -0.07 (-0.07) after...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
